Passa al contenuto
Merck
  • The first Korean case of lysinuric protein intolerance: presented with short stature and increased somnolence.

The first Korean case of lysinuric protein intolerance: presented with short stature and increased somnolence.

Journal of Korean medical science (2012-08-10)
Jung Min Ko, Choong Ho Shin, Sei Won Yang, Moon Woo Seong, Sung Sup Park, Junghan Song
ABSTRACT

Lysinuric protein intolerance (LPI) is a rare inherited metabolic disease, caused by defective transport of dibasic amino acids. Failure to thrive, hepatosplenomegaly, hematological abnormalities, and hyperammonemic crisis are major clinical features. However, there has been no reported Korean patient with LPI as of yet. We recently encountered a 3.7-yr-old Korean girl with LPI and the diagnosis was confirmed by amino acid analyses and the SLC7A7 gene analysis. Her initial chief complaint was short stature below the 3rd percentile and increased somnolence for several months. Hepatosplenomegaly was noted, as were anemia, leukopenia, elevated levels of ferritin and lactate dehydrogenase, and hyperammonemia. Lysine, arginine, and ornithine levels were low in plasma and high in urine. The patient was a homozygote with a splicing site mutation of IVS4+1G > A in the SLC7A7. With the implementation of a low protein diet, sodium benzoate, citrulline and L-carnitine supplementation, anemia, hyperferritinemia, and hyperammonemia were improved, and normal growth velocity was observed.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Supelco
Benzoato sodico, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Benzoato sodico, ReagentPlus®, 99%
Sigma-Aldrich
Benzoato sodico, puriss., meets analytical specification of Ph. Eur., BP, FCC, E211, 99.0-100.5% (calc. to the dried substance), powder
Sigma-Aldrich
Benzoato sodico, BioXtra, ≥99.5%
Sigma-Aldrich
Benzoato sodico, purum p.a., ≥99.0% (NT)